基石藥業-B(02616.HK)擬折讓8.88%配售合共1億股配售股份 總籌4.72億港元
格隆匯7月9日丨基石藥業-B(02616.HK)發佈公告,2025年7月8日,公司與配售代理(即摩根士丹利)訂立配售協議,據此,公司已有條件同意透過配售代理,以每股配售股份4.72港元的價格,向不少於六名承配人配售合共1億股配售股份。每股配售股份配售價爲4.72港元,較2025年7月8日(即緊接配售協議日期前最後一個完整交易日)聯交所呈報的收市價每股股份5.18港元折讓約8.88%。
最多1億股配售股份將佔本公告日期公司現有已發行股本約7.33%及緊隨配售後經擴大已發行股本約6.83%(假設自本公告日期起直至配售完成日期止公司的已發行股本並無變動)。配售股份將根據一般授權配發及發行,且無需取得任何股東批準。
公司是一家專注於抗腫瘤藥物研發的創新型生物製藥公司,以滿足中國和全球患者的醫療需求。假設所有配售股份悉數獲配售,則配售估計所得款項總額及淨額將分別爲約4.72億港元及約4.67億港元。配售所得款項淨額預期將用於以下用途:(i)90%用於與集團“管線2.0”中的資產,尤其是CS2009(一款靶向PD-1、VEGFA及CTLA-4的三特異性分子,潛在同類首創╱同類最優的下一代腫瘤免疫骨架)、CS5001(一款處於臨牀階段的ROR1 ADC(潛在同類最佳ROR1 ADC))以及CS2015(一款靶向OX40L及TSLP的雙抗)等臨牀前資產有關的進一步研發;及(ii)餘下所得款項淨額於適當時用於其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.